Videos

Addition of Durvalumab, Bevacizumab to TACE for Hepatocellular Carcinoma Improves PFS

Featuring Riccardo Lencioni, MD

01/23/2024

At the ASCO Gastrointesinal Cancers Symposium, Riccardo Lencioni, MD, Pisa University School of Medicine, Pisa, Italy, discussed the results from the phase 3 EMERALD-1 study. This trial found the combination of transarterial chemoembolization (TACE) and durvalumab, followed by durvalumab and bevacizumab, improved the progression-free survival (PFS) among patients with hepatocellular carcinoma, compared with TACE alone.

Source:

Lencioni R, Kudo M, Erinjeri J, et al. EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. Presented at 2024 ASCO Gastrointestinal Cancer Symposium; January 18-20, 2024; San Francisco, California. Abstract LBA432

© 2023 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.

IO Learning Newsletter

News

Novel Endovascular Robotic Surgical System Reaches Midpoint of Pivotal Clinical Trial

09/20/2024

Allison Casey ;

The ACCESS-PVI trial of LIBERTY® Endovascular Robotic Surgical System has enrolled and completed follow-up for 50% of patients.

The ACCESS-PVI trial of LIBERTY®...

09/20/2024

IO Learning

News

Histotripsy Demonstrates Technical Success, Safety for Primary and Metastatic Liver Tumors

09/04/2024

Allison Casey ;

According to results from the parallel #HOPE4LIVER trials, the novel ablation technique of histotripsy met coprimary end points for technical success and safety among patients with primary and metastatic liver tumors.

According to results from the...

09/04/2024

IO Learning

News

Sorafenib Plus Transarterial Chemoembolization Improves Survival Outcomes, Response Among Patients With Recurrent Hepatocellular Carcinoma

07/29/2024

Allison Casey ;

According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.

According to a phase 3 trial,...

07/29/2024

Oncology

News

Thermal Ablation Over Surgical Resection for Patients With Smaller Colorectal Liver Metastases

07/18/2024

Allison Casey ;

According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.

According to the phase 3...

07/18/2024

IO Learning

News

Manageable Safety Across Treatment Periods for Durvalumab, Bevacizumab, and TACE Regimen Among Patients With Unresectable Hepatocellular Carcinoma

07/17/2024

Allison Casey ;

According to a post-hoc, exploratory analysis of safety by treatment period in the EMERALD-1 study, durvalumab plus bevacizumab plus transarterial chemoembolization had a manageable safety profile across both treatment periods among patients...

According to a post-hoc,...

07/17/2024

IO Learning

News

Transit Scientific Announces First Worldwide Case Performed with Innovative Embolic-Delivery Microcatheter

07/09/2024

Transit Scientific Press Release Park City, Utah USA, July 9, 2024 – Transit Scientific, a Utah-based medical device company specializing in innovative solutions for vascular procedures, proudly announces the successful debut of XO...

Transit Scientific Press...

07/09/2024

Vascular Disease Management

Imaging Systems

University Hospitals Cleveland, Siemens Healthineers in New Alliance to Improve Oncology, Cardiovascular and Neurovascular Care for Patients

05/08/2024

Siemens Healthineers and University Hospitals Cleveland News

Siemens Healthineers and University H...

The new alliance will enhance cardiovascular services of the UH Harrington Heart & Vascular Institute with the world’s first clinically available photon-counting CT scanner and the new dual-source CT scanner.

The new alliance will enhance...

05/08/2024

Cath Lab Digest

News

Histotripsy Treatment for Primary and Metastatic Liver Tumors

04/25/2024

Allison Casey ;

At the 2023 CIRSE Annual Meeting, first results from the #HOPE4LIVER trial evaluating histotripsy for primary and metastatic liver tumors were reported.

At the 2023 CIRSE Annual...

04/25/2024

IO Learning

News

First-of-Its-Kind Surgical Foam Technology Improves Operating Room Workflow

04/24/2024

Syntervention Press Release

Rocky Mount, North Carolina, USA, April 24, 2024 — Syntervention, Inc., a medical device company focused on meeting critical needs in the healthcare space, announces the impact of using its SWICKER® Radiopaque Surgical Foam Sponge in open...

Rocky Mount, North Carolina,...

04/24/2024

EP Lab Digest

News

Fluidx Medical Reveals New Embolic Platform for Internal Bleeding, Tumor Treatment, and Other Uses

11/30/2023

Salt Lake City (UT) – Fluidx Medical today released information about their new ULTRA™ embolic platform designed to make therapeutic embolization procedures safer, better, and faster.   Embolization is a minimally invasive...

Salt Lake City (UT) – Fluidx...

11/30/2023

Vascular Disease Management

Insights from the ASCO GI Cancers Symposium

Addition of Durvalumab, Bevacizumab to TACE for Hepatocellular Carcinoma Improves PFS

Source:

© 2023 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.

Subscribe

News

Specialties

Events

Year Round Education

HMP Global Products

Insights from the ASCO GI Cancers Symposium

Addition of Durvalumab, Bevacizumab to TACE for Hepatocellular Carcinoma Improves PFS

Source:

© 2023 HMP Global. All Rights Reserved.Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.

Subscribe

News

Specialties

Events

Year Round Education

HMP Global Products

© 2023 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.